pTrc99S-ssDsbA-MBP-4xDQNAT
(Plasmid
#128398)
-
PurposePeriplasmic expression of E. coli MBP with C terminal 4xDQNAT glycosylation sites in E. coli
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 128398 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepTrc99S
- Backbone size w/o insert (bp) 4535
- Total vector size (bp) 5763
-
Vector typeBacterial Expression
Growth in Bacteria
-
Bacterial Resistance(s)Spectinomycin and Streptomycin, 50 & 50 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Copy numberLow Copy
Gene/Insert
-
Gene/Insert nameMaltose binding protein
-
SpeciesE. coli
-
Insert Size (bp)1227
-
MutationY342H- please see depositor comments
- Promoter trc
-
Tags
/ Fusion Proteins
- 4xDQNAT glycosylation tag (C terminal on insert)
- 6xHis tag (C terminal on insert)
- DsbA signal sequence for periplasmic translocation (N terminal on backbone)
Cloning Information
- Cloning method Gibson Cloning
- 5′ sequencing primer GACAATTAATCATCCGGCTCG
- 3′ sequencing primer GATTTAATCTGTATCAGG (Common Sequencing Primers)
Resource Information
-
Supplemental Documents
-
A portion of this plasmid was derived from a plasmid made byE. coli MBP 4xDQNAT is from pTrc99A-MBP-4x-DQNAT Valderrama-Rincon, et al. doi.org/10.1038/nchembio.921
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
Depositor Comments
Depositor confirms mutation Y342H does not affect plasmid function.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pTrc99S-ssDsbA-MBP-4xDQNAT was a gift from Michael Jewett (Addgene plasmid # 128398 ; http://n2t.net/addgene:128398 ; RRID:Addgene_128398) -
For your References section:
On-demand biomanufacturing of protective conjugate vaccines. Stark JC, Jaroentomeechai T, Moeller TD, Hershewe JM, Warfel KF, Moricz BS, Martini AM, Dubner RS, Hsu KJ, Stevenson TC, Jones BD, DeLisa MP, Jewett MC. Sci Adv. 2021 Feb 3;7(6). pii: 7/6/eabe9444. doi: 10.1126/sciadv.abe9444. Print 2021 Feb. 10.1126/sciadv.abe9444 PubMed 33536221